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Abstract
Purpose Selenium is frequently in nutraceuticals for pregnancy, given its role on fertility and thyroid metabolism. However,
most evidence rise from non-controlled studies. We aimed to evaluate the protective effect of selenium against thyroid
autoimmunity during and after pregnancy.
Methods A multicenter, randomized, double-blind, placebo-controlled trial was performed and promoted by the Young
Italian Endocrinologists Group (EnGioI)—Italian Society of Endocrinology. Forty-ﬁve women with thyroiditis in pregnancy
were enrolled and randomly assigned to L-selenomethionine (L-Se-Met) 83 mcg/day or placebo (PLB) and evaluated at 10 ±
2 (T1), 36 ± 2 weeks of gestation (T2) and 6 months after delivery (postpartum, PP).
Results We measured a signiﬁcant reduction of autoantibodies after pregnancy in L-Se-Met group [at PP: TgAb 19.86
(11.59–52.60), p < 0.01; TPOAb 255.00 (79.00–292.00), p < 0.01], and an antibodies titer’s rebound in PLB group (TgAb
151.03 ± 182.9, p < 0.01; TPOAb 441.28 ± 512.18, p < 0.01). A signiﬁcant increase in selenemia was measured in L-Se-Met
group at T2 (91.33 ± 25.49; p < 0.01) and PP (93.55 ± 23.53; p= 0.02). Two miscarriage occurred in PLB. No differences
were found in thyroid volume, echogenicity, quality of life, maternal/fetal complications.
Conclusions SERENA study demonstrated a beneﬁcial effect of L-Se-Met supplementation on autoantibody titer during
pregnancy and on postpartum thyroiditis recurrence.
Keywords L-selenomethionine ● Autoimmune thyroiditis ● Maternal complications ● Fetal risk
Introduction
Over the last 30 years, it has become clear that thyroid
autoimmunity, including Graves’ disease, is correlated with a
series of maternal and fetal risks during pregnancy and with
female infertility [1–8]. Research has led to different propo-
sals for acting on the target of thyroid autoimmunity. It has
been suggested that levothyroxin (LT4) replacement therapy
reduces the risk of abortion and preterm birth, although this
effect disappears once euthyroidism is reached [9, 10].
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Recent years have seen a dramatic rise in food supple-
ments recommended or suggested during pregnancy. There
is evidence that selenium supplementation reduces the
antibody titer in the course of thyroiditis, improving
glandular echogenicity in a sample of male and female
patients [11], while women with a history of recurrent
pregnancy loss have low blood selenium levels [12]. Fur-
thermore, low selenium levels are associated with an
increased prevalence of thyroid disease [13].
Data about the effects of selenium supplementation are
sparse and are needed [14–16]. The aim of the present study
is to establish if selenium supplementation has any protec-
tive effect on thyroid autoimmunity during and after
pregnancy.
Subjects and methods
Study design
We designed a multicenter, randomized, double-blind,
placebo-controlled trial to evaluate the effects of
L-selenomethionine (L-Se-Met) supplementation on anti-
body titer in euthyroid pregnant women with positive
antithyroid antibodies. Secondary outcomes included thyr-
oid hormones; thyroid volume and echogenicity; delivery,
obstetrical, fetal, and neonatal complications; and health-
related quality of life (HRQOL). Ten Italian endocrinology
and gynecology referral centers took part in the study, for
which the Department of Experimental Medicine and
Endocrinology, “Sapienza” University of Rome was the
coordinating center. The study was promoted and supported
by the Young Italian Endocrinologists Group (EnGioI) of
the Italian Society of Endocrinology (SIE). The study was
approved by Ethical Committee of Policlinico Umberto I
Hospital, “Sapienza” University of Rome. All procedures
performed in studies involving human participants were in
accordance with the ethical standards of the institutional
and/or national research committee and with the 1964
Helsinki declaration and its later amendments or compar-
able ethical standards. After protocol was approved by the
institutional review board at each center. Informed consent
was obtained from all participants after a full explanation of
the purpose and nature of all procedures involved.
Participants
Women aged between 18 and 45 years who were positive
for thyroglobulin antibodies (TgAb) and/or thyroid perox-
idase autoantibodies (TPOAb) and who were pregnant
(4–8 ± 2 weeks of gestation) were included in the study. The
enrollment period was between November 2011 and
November 2016 (end of treatment, January 2018). Serum
TSH was tested at the screening visit (T0) and levothyr-
oxine (LT4) treatment was initiated or adjusted for TSH
values above 2.7 mIU/L [17–19].
The exclusion criteria were as follows: use of corticos-
teroids, anti-inﬂammatory drugs, vitamins, food supple-
ments, trace elements, antidepressants/antipsychotics,
amiodarone, propanolol, and/or lithium; history of hyper-
thyroidism; positive anti-thyrotropin antibodies; previous
partial or total thyroidectomy; known fetal anomaly; known
thrombophilia; known infections and mola hydatidoses;
chronic renal failure; uncontrolled hypertension; known
placental abnormalities; uterine malformation; history of
medical and metabolic complications such as heart disease
or diabetes; and refusal of consent to data collection in line
with Italian privacy laws.
Setting and methods
The patients were randomly divided into two groups.
Patients in group A received L-Se-Met soft gel caps 83 mcg/
day, while those in group B received placebo (PLB) (Fig. 1).
All patients were treated for the entire duration of pregnancy
and for 6 months after delivery. Follow-up visits took place
at 10 ± 2 weeks (T1), 36 ± 2 weeks (T2) of gestation and
6 months after delivery (postpartum, PP). Each visit com-
prised gestational, obstetrical, maternal, and fetal history;
physical examination; thyroid hormones; TPOAb and
TgAb; serum selenium concentration; thyroid ultrasound
(US); and the short form 12-item (SF12) questionnaire.
Data were collected by the participating centers using
electronic case report forms (eCRF) at the baseline and at
follow-up visits.
Laboratory investigations
Serum samples were analyzed at a central laboratory. Serum
TSH, FT3, FT4, and Ab titers were measured using a third-
generation electrochemiluminescence immunoassay
(Abbott, Rome, Italy). The reference laboratory values were
0.35–4.94 mIU/L for TSH, 1.71–3.71 pg/L for FT3, and
0.7–1.48 ng/dl for FT4. TgAb were considered positive
when above 4.11 IU/L; TPOAb were considered positive
when above 5.61 IU/L.
Serum selenium concentration (Se) was determined by
open-vessel acid digestion of small serum volumes (200 μL)
followed by atomic ﬂuorescence spectroscopy (FullTech
Instruments, Rome, Italy), according to a method demon-
strated in a previous study published by our group [20].
Thyroid ultrasound
Thyroid ultrasound (US) was performed in each partici-
pating center using an ultrasound scanner with a 7.5MHz
Endocrine
linear real-time transducer [21, 22]. The images were
entered in the eCRF and analyzed by the coordinating
center to calculate thyroid volume and to evaluate thyroid
echogenicity.
Thyroid volume was computed measuring the maximum
width, thickness, and length in both lobes of the thyroid
gland. The lobes were approximated to ellipsoids and the
maximum volume of each lobe was calculated using the
formula: volume of one lobe (mL)= length (mm) × width
(mm) × depth (mm) × 0.479. The total thyroid volume was
obtained by adding together the volumes of each lobe [23].
Constant operating conditions were deﬁned for the
measurement of thyroid echogenicity. The following para-
meters were adjusted before each US analysis: US power
level (high), brightness gain (30 dB), depth range
(30–60 dB, graduated), frame rate (21/min), B-mode
dynamic range, B-mode enhancement level, and scan cor-
relation. The US instrument settings were kept exactly the
same for each patient at each follow-up visit to ensure that
any differences in thyroid echogenicity reﬂected real
changes in gland structure and not inter-assay variations. To
compare thyroid echogenicity at each visit, all images were
further analyzed ofﬂine using a widespread imaging ana-
lysis program available for download in the public domain
(ImageJ, 1.49q, NIH, USA). Thyroid echogenicity was
measured as described previously [11].
SF12
HRQOL was evaluated at each visit with the SF12 ques-
tionnaire. SF12 was developed in 1994 in English as a
shorter alternative to the SF36 [24]. It consists of eight
subscales, grouped into two scales: a physical component
score (PCS) and a mental component score (MCS), in
accordance with the SF12 guidelines. Both scores range
between 0 and 100, with a higher score indicating better
health [25].
Statistical methods
All data were entered in the eCRF and a database was cre-
ated at the coordinating center. Statistical analysis was per-
formed using SAS v. 9.4 (SAS Institute Inc., Cary, NC,
USA). Normality of the continuous variables was tested with
the Shapiro–Wilk test. Normally continuous variables were
presented as mean ± SD, while those not normally dis-
tributed were presented as median (25th–75th percentile).
The differences in the continuous variables between the two
groups (Placebo vs. L-Se-Met) were tested by Student’s T
test when data were normal or log-transformed and by
Mann–Whitney U test when data were not normally dis-
tributed. For dependent data the paired T test was used when
data were normally distributed or log-transformed, while
Wilcoxon’s test was used for non-normally distributed data.
p < 0.05 was considered to be statistically signiﬁcant.
Results
Forty-ﬁve pregnant women with a mean age of 33.3 ± 4.9
years were enrolled. The mean BMI was 23.5 ± 4.1. Forty
patients were nulliparous. At T1 32 patients were already
taking LT4. Three patients started LT4 treatment. Ten
patients required an LT4 dosage adjustment during preg-
nancy. After delivery, 10 patients reduced their LT4 dosage
but no one stopped the therapy. There were no signiﬁcant
Fig. 1 Study ﬂowchart. L-Se-
Met indicates L-
seleniomethionine; P.E.,
physical examination; thyroid U.
S., thyroid ultrasonography; SF-
12 questionnaire, Quality of life
assessment using the Short
Form-12 Health survey
questionnaire
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differences between the L-Se-Met and PLB groups at T1
(Table 1).
Autoantibody titer
There were no signiﬁcant differences in TgAb between the
groups at T1 (L-Se-Met group 87.20 ± 199.30; PLB group
54.36 ± 66.66; p= 0.93) (Table 1). In both groups, TgAb
values decreased signiﬁcantly from T1 to T2 [L-Se-Met
group T2 6.03 (2.82–27.67); p < 0.01; PLB group T2
26.38 ± 36.10; p= 0.05]. In the PLB group TgAb increased
signiﬁcantly from T2 to PP (151.03 ± 182.9; p < 0.01), but
in the L-Se-Met group it dropped signiﬁcantly from baseline
[19.86 (11.59–52.60); p < 0.01] (Table 2 and Fig. 2).
Regarding TPOAb values, there were no signiﬁcant
differences between the groups at T1 [L-Se-Met group
159.00 (50.21–570.00); PLB group 86.93 (6.51–71.70);
p= 0.6] (Table 1). TPOAb decreased signiﬁcantly in both
groups from T1 to T2 [L-Se-Met group 61.58
(20.10–148.75); p= 0.01; PLB group 61.04 ± 70.91; p=
0.04]. In the PLB group TPOAb values increased sig-
niﬁcantly from T2 to PP (441.28 ± 512.18; p < 0.01), while
Table 1 Baseline characteristics of the 45 randomized subjects
Group A
L-Se-Met
n= 21
Group B
PLB
n= 24
p Value
Age (years) 32.2 ± 4.9
mean ± SD
34.3 ± 4.7
mean ± SD
0.21
BMI (kg/m2) 23.4 ± 4.2
mean ± SD
23.6 ± 4.2
mean ± SD
0.51
Systolic blood
pressure (mmHg)
100.00 ± 14.83
mean ± SD
110.00 ± 8.90
mean ± SD
0.18
Diastolic blood
pressure (mmHg)
62.50 ± 7.41
mean ± SD
70.00 ± 7.41 0.89
Nulliparous (%) 20 (66.7%) 20 (76.9%) 0.41
Week of gestation 9.61 ± 2.28
mean ± SD
10.09 ± 2.91
mean ± SD
0.85
TSH (mcIU/L) 1.77 (0.90–2.48)
median (25th–75th
percentile)
1.21 (0.68–1.82)
median (25th–75th
percentile)
0.42
FT3 (pg/mL) 2.85 (2.56–3.09)
median (25th–75th
percentile)
2.81 (2.59–3.09)
median (25th–75th
percentile)
0.79
FT4 (ng/dL) 1.17 ± 0.14
mean ± SD
1.07 ± 0.14
mean ± SD
0.86
AbTG (IU/mL) 87.20 ± 199.30 54.36 ± 66.66 0.93
AbTPO (IU/mL) 159.00
(50.21–570.00)
median (25th–75th
percentile)
86.93
(6.51–71.70)
median (25th–75th
percentile)
0.60
Serum selenium
concentration (mcg/L)
63.00
(54.00–69.00)
median (25th–75th
percentile)
66.00
(54.00–78.00)
median (25th–75th
percentile)
0.63
Normally continuous variables were presented as mean ± SD, while
those not normally distributed were presented as median (25th–75th
percentile)
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Endocrine
in the L-Se-Met group they dropped signiﬁcantly [255.00
(79.00–292.00); p < 0.01] (Table 2 and Fig. 3).
Thyroid function
There were not signiﬁcant differences in TSH values in both
groups at T1 [L-Se-Met group: 1.77 (0.90–2.48); PLB
group 1.21 (0.68–1.82); p= 0.42] (Table 1) and decreased
in both groups from T1 to T2 [L-Se-Met group T2 0.87
(0.55–1.18); p= 0.2; PLB group T2 0.87 (0.45–1.04; p=
0.09]. TSH values tended to increase in both groups from
T2 to PP although the difference was not statistically sig-
niﬁcant [L-Se-Met group PP 1.44 (1.11–3.02); p= 0.2;
PLB group PP 1.39 (0.05–5.07); p= 0.04)] (Table 2). There
were no statistically signiﬁcant differences in FT3 and FT4
throughout pregnancy or at PP in either group.
Serum selenium concentration
No signiﬁcant differences were measured in serum selenium
concentration (Se) in both groups at T1 [L-Se-Met group:
63.00 (54.00–69.00); PLB group: 66.00 (54.00–78.00); p=
0.63] (Table 1). In the PLB group Se decreased signiﬁcantly
from T1 to T2 (T2 56.24 ± 19.48; p < 0.01), subsequently
increasing from T2 to PP (PP 71.08 ± 18.83; p < 0.01). Se
was signiﬁcantly higher in the L-Se-Met group than in the
PLB group at both T2 (L-Se-Met: 91.33 ± 25.49; PLB:
56.24 ± 19.48; p < 0.01) and PP (L-Se-Met: 93.55 ± 23.53;
PLB: 71.08 ± 18.83; p= 0.02) (Table 2).
Thyroid US
At T1, no signiﬁcant differences were measured thyroid
echogenicity (TE) in the two groups (L-Se-Met group 64.50 ±
49.00; PLB group 47.80 ± 35.00; p= 0.09). It did not change
signiﬁcantly in either group during pregnancy or by PP.
Thyroid volume was 8.15 ± 5.09 mL in the PLB group
and 6.14 ± 2.35 mL in the L-Se-Met group; this difference
was not statistically signiﬁcant (p= 0.37). At T2 and PP,
thyroid volume remained stable in both groups, again
without any statistically signiﬁcant inter-group difference
(T2: p= 0.36; T2: p= 0.54).
Health-related quality of life (HRQOL)
No signiﬁcant differences were measured in HRQOL for
both groups (L-Se-Met group: 31.07 ± 1.83; PLB group:
30.67 ± 2.40; p= 0.61). SF12 did not vary signiﬁcantly in
either group at T2 (p= 0.98) or PP (p= 0.99).
Maternal risk
None of the women included in the study had a history of
gestational diabetes, nor did they present gestational dia-
betes during the trial. We included among the adverse
pregnancy outcomes the following: pre-eclampsia (gesta-
tional hypertension: systolic pressure ≥ 140 mmHg or dia-
stolic blood pressure ≥ 90 mmHg [Korotkoff V] on ≥2
occasions after 20 weeks gestation), miscarriage, placental
abruption, abruption, gestational hypertension, gestational
diabetes, breech presentation at birth, preterm birth
(<37 weeks gestation), symptomatic hypothyroidism, pre-
term labor, postpartum hemorrhage, postpartum depression,
and maternal death.
Discussion
This multicenter, randomized, double-blind, placebo-
controlled study evaluated the effects of L-Se-Met
Fig. 2 TgAb trends during and after pregnancy in L-Se-Met and
PLB groups
Fig. 3 TPOAb trends during and after pregnancy in L-Se-Met and
PLB groups
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supplementation on antibody titer in euthyroid pregnant
women with positive anti-thyroid antibodies. During preg-
nancy (from T0 to T2), TgAb and TPOAb decreased sig-
niﬁcantly in both groups, reﬂecting the general reduction in
maternal immune response typical of this period to prevent
rejection of the fetus. In contrast, at PP there was still a
signiﬁcant decrease in the L-Se-Met group but a signiﬁcant
increase in these antibodies in the PLB group.
Women who are thyroid Ab positive in the ﬁrst trimester
of pregnancy have a high risk of developing post-partum
thyroiditis (PPT), with a prevalence ranging from 33 to 50%
[26]. The higher the autoantibody titer, the higher the risk of
developing PPT [27]. The clinical course of PPT can vary.
Generally, hypothyroidism occurs from 3 to 12 months after
delivery. A prospective study showed that 50% of women
with PPT have permanent hypothyroidism at the end of the
ﬁrst postpartum year [28]. In 1990, Kampe et al. examined the
inﬂuence of LT4 and iodide in preventing PPT, but neither
intervention seemed to alter the course of PPT [29]. In 2007,
Negro et al. evaluated the effect of Se-Met 200mcg/day
administered during and after pregnancy on thyroid function,
autoimmunity, and echogenicity patterns, ﬁnding that it
reduced the incidence of PPT and hypothyroidism, reduced
TPOAb titers, and ameliorated the US echogenicity pattern in
comparison with controls [30]. However, in another recent
randomized clinical trial 230 women with singleton preg-
nancies were randomized to receive 60 μg/day selenium or
placebo until delivery. Selenium supplementation was no
more beneﬁcial than placebo in reducing TPO-Ab con-
centration, though it tended to inﬂuence thyroid function in
women with positive autoantibodies [31].
Furthermore, some studies evaluating non-pregnant
women have shown that selenium can have an effect in
reducing TPOAb concentrations [32–35]. Only one study,
on 36 patients with autoimmune thyroiditis, found that
sodium selenite (200 mcg per day) administered for
3 months did not induce signiﬁcant immunological changes
(cytokine production patterns of peripheral T lymphocytes/
TPOAb levels).
Selenium supplementation seems to have an effect on
thyroid function only in cases of selenium deﬁciency [36].
Two trials investigating selenium supplementation in a
population of euthyroid women with autoimmune thyr-
oiditis found that neither selenite nor selenomethionine had
any effect on thyroid hormone concentrations [37, 38].
In our population, 32 patients (71.1%) were taking LT4
at T1, 10 patients (22.2%) required LT4 dosage adjustment
during pregnancy, and three patients (6.7%) began LT4
treatment between the 10th and the 20th week of gestation.
LT4 treatment was started or adjusted to maintain TSH
values below 2.7 mIU/L, in accordance with current inter-
national guidelines [17, 39]. After delivery, 12 patients
(26.7%) reduced their LT4 dosage but no one stopped the
therapy. Despite this, 6 months after delivery there was a
clinically signiﬁcant (albeit non-statistically signiﬁcant)
increase in TSH values in the PLB group.
This study used HG-AFS as a fast, new, and reliable
technique to analyze selenium absorption and bioavail-
ability, ﬁrst validated in a previous study on 30 healthy
volunteers published by our group. This method offers an
economical way to quantify selenium and hence manage
thyroid metabolism in various conditions for which L-Se-
Met supplementation is recommended, such as autoimmune
thyroiditis and pregnancy [20]. We did not measure urine
selenium given previous data showing low association
between urine selenium changes and thyroid autoimmune
activity during pregnancy [40].
The present study describes the pharmacokinetics prop-
erties of serum selenium concentration (Se) throughout
pregnancy and at 6 months after delivery. The baseline Se
in our sample was below the normal range. According to
existing data, the optimal range should be considered as
80–120 mcg/L. Low Se has been associated with seleno-
protein underactivity, especially of GPXs [16].
Subsequently, between T1 and T2 we observed an
additional signiﬁcant reduction in Se, followed in the PLB
group by a signiﬁcant increase at PP. This trend conﬁrms
the results of previous studies [30, 41, 42]. Nevertheless,
low Se in pregnant women has in part been explained by the
hemodilution typical of pregnancy [43]. However, the
decline in Se during pregnancy should not be dismissed,
because of the risk of developing severe selenium deﬁ-
ciency and pregnancy complications.
Thyroid echogenicity and volume during pregnancy
were not inﬂuenced by L-Se-Met administration in our
study. Two trials that investigated thyroid volume and
echogenicity qualitatively found that 200 μg of sodium
selenite/day improved echogenicity after 3 and 9 months
[32, 44]. These data were conﬁrmed in a quantitative ana-
lysis by Nacamulli et al., who reported greater hypoecho-
genicity in controls, as compared to the intervention group,
after 12 months of 80 μg sodium selenite/day [11].
To our knowledge, this is the ﬁrst evaluation of the
effects of L-Se-Met supplementation on HRQOL in preg-
nancy using SF12. We did not observe any signiﬁcant
differences between the L-Se-Met and PLB groups at the
baseline, during pregnancy or 6 months after delivery.
Two double-blinded trials using the SF-36 form found no
signiﬁcant changes in HRQOL following 6 or 12 months of
selenium supplementation in patients not treated with LT4
[37, 38]. Two studies using the SF-12 form found a sig-
niﬁcant improvement in wellbeing after 200 μg/day of sodium
selenite for 3 months compared to placebo [32, 45]. A sig-
niﬁcant beneﬁcial effect of selenium administration on
HRQOL was also demonstrated in a randomized, double-
blind, placebo-controlled trial comparing 200mcg/day
Endocrine
sodium selenite to 1200mg/day pentoxifylline or placebo for
6 months in 159 patients with mild Graves’ orbitopathy [46].
Conclusions
The SERENA study demonstrated that selenium supple-
mentation at a dosage of 83 mcg/day during pregnancy and
after delivery is safe and has a beneﬁcial effect on auto-
antibody titer and on postpartum thyroiditis recurrence.
Selenium supplementation during pregnancy did not affect
thyroid hormones, thyroid ultrasound, or HRQOL. No dif-
ferences were found in adverse pregnancy outcomes.
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